Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of acute myocardial infarction in the sub-arctic region of Norway. Do we offer an equal quality of care?

International journal of circumpolar health·2017
Same author

Delay in diagnosis and treatment of breast cancer in northern Norway.

Oncology reports·2011
Same author

Quality of life (QoL) measurement in economical analysis in cancer.

Oncology reports·2011
Same author

Quality of life in Dukes' B and C colorectal carcinoma.

Oncology reports·2011
Same author

Breast conserving surgery (BCS) in northern Norway.

International journal of oncology·2011
Same author

Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.

Journal of chemotherapy (Florence, Italy)·2010

Related Experiment Video

Updated: Jun 1, 2026

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Radiotherapy costs in glioblastoma.

J Norum

    Oncology Reports
    |May 20, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Radiotherapy for glioblastoma in northern Norway showed that prolonged treatment is cost-effective only when survival benefits exceed two months and is administered in an outpatient setting. This analysis informs future glioblastoma treatment strategies.

    More Related Videos

    An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
    09:10

    An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

    Published on: November 15, 2024

    Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
    07:57

    Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

    Published on: March 24, 2022

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
    09:10

    An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

    Published on: November 15, 2024

    Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
    07:57

    Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

    Published on: March 24, 2022

    Area of Science:

    • Oncology
    • Health Economics

    Background:

    • Glioblastoma is an aggressive brain tumor with limited treatment options.
    • Radiotherapy is a standard treatment modality for glioblastoma.
    • Understanding the cost-effectiveness of different radiotherapy regimens is crucial for resource allocation.

    Purpose of the Study:

    • To determine the cost-effectiveness of two different radiotherapy doses (54 Gy and 39 Gy) for glioblastoma patients.
    • To analyze the cost utility and perform sensitivity analyses for radiotherapy in glioblastoma treatment.

    Main Methods:

    • Retrospective study of 29 glioblastoma patients treated between 1987-1992 in northern Norway.
    • Patients received either 54 Gy (9 patients) or 39 Gy (10 patients) of radiotherapy.
    • Treatment costs were calculated using 1994 prices, with cost-effectiveness and cost utility analyses performed.

    Main Results:

    • Median survival was 12 months for the 54 Gy group and 7 months for the 39 Gy group.
    • The cost-effective analysis indicated a treatment cost of £4,858 per year of life saved.
    • Prolonged radiotherapy was cost-effective only with a survival benefit greater than two months and in an outpatient setting.

    Conclusions:

    • The cost-effectiveness of prolonged radiotherapy for glioblastoma is highly dependent on the achieved survival benefit and treatment setting.
    • Outpatient radiotherapy with a survival benefit exceeding two months presents a potentially cost-effective strategy for glioblastoma.
    • Further research into optimizing radiotherapy delivery and assessing long-term outcomes is warranted.